OBJECTIVE
To examine the current EU5 market access landscape for ATMPs
METHODS
Assessed the regulatory path, HTA and reimbursement for ATMPs with European Commission (EC) approval as of September 2018
BACKGROUND
• Advanced therapy medicinal products (ATMPs) are medicines for human use that are based on genes, tissues or cells
• ATMPs can be classified into three main types:
1. Gene therapy medicines: these contain genes that lead to a therapeutic, prophylactic or diagnostic effect 2. Somatic-cell therapy medicines: these contain cells or tissues that have been manipulated to change their biological characteristics or cells or tissues not intended to be used for the same essential functions in the body. They can be used to cure, diagnose or prevent diseases; 3. Tissue-engineered medicines: these contain cells or tissues that have been modified so they can be used to repair, regenerate or replace human tissue;
• Steady stream of promising clinical results for ATMPs shows progress in the field
• However numerous challenges still exist, in particular, significant R&D investment and market access / commercialization hurdles 
CONCLUSIONS
• Almost nine years since the first ATMP was approved, market access remains challenging, particularly in France and Spain where none of the ATMPs currently available in Europe are accessible to patients through normal channels
• On the other hand, countries like Germany, Italy and the UK seem to be developing market access pathways primarily based on conditional reimbursement and outcomes/ financial based agreements
• Evolution of payment models and adaptation by countries will continue, as more ATMPs are launched, bringing important health benefits, but also impacting pharmaceutical budgets given the high costs associated with these therapies MME -France: None of the ATMPs are currently reimbursed through normal channels
Only one evaluation completed by the HAS, with price negotiations still ongoing -Germany: All 8 ATMPs are authorized by the Paul Ehrlich Institute G-BA reviews under AMNOG have been completed for two drugs, one assigned 'no added benefit' (Imlygic) and another 'non-quantifiable added benefit' (Zalmoxis). Of the remaining 6 ATMPS:
• 2 ATMPs not assessed by the G-BA because they are classified as procedures and not drugs (Holoclar and Spherox)
• 2 are not marketed in Germany and therefore not listed on Lauer-Taxe or reviewed by the G-BA (Strimvelis, Yescarta)
• Reviews are ongoing for the remaining two (Alofisel, Kymriah)
Reimbursement is available only for the 4 ATMPs listed on the Lauer-Taxe 
